Search | IOVS | ARVO Journals

View

Showing 1 – 8 of 8

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2018

Ocular Safety of AAV2.7m8-ChrimsonR-tdTomato (GS030-DP) following intravitreous injection and exposure to 595 nm LED light in blind rd1 mice

Brian J Christian; Steven D Sorden; Michael Ward; T Michael Nork; Paul E Miller; Anne Douar; Nitza Thomasson; Celine Bouquet

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5658. doi:

ARVO Annual Meeting Abstract July 2018

Intravitreal injection of rAAV2/2- ND4 in LHON: absence of correlation between ocular inflammation and humoral or cellular immune responses to AAV2

Barrett Katz; Anne Galy; Serge Fitoussi; Catherine Vignal Clermont; Jose A. Sahel; Catherine Cancian; Nitza Thomasson; Celine BOUQUET

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4531. doi:

ARVO Annual Meeting Abstract July 2018

Impact of sequential bilateral intravitreal injection of rAAV2/2- ND4 on ocular and systemic humoral immune status in non-human primates

Celine BOUQUET; Anne Galy; Catherine Cancian; Nitza Thomasson

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4537. doi:

ARVO Annual Meeting Abstract June 2017

Phase I/IIa Visual Acuity Outcomes 1.5-Years Post-Treatment with rAAV2/2- ND4, an Investigational Gene Therapy for ND4 LHON

Scott Uretsky; Nitza Thomasson; Celine BOUQUET; Anne Galy; Jean Philppe Combal; Serge Fitoussi; Jose Alain Sahel; Catherine Vignal

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4681. doi:

ARVO Annual Meeting Abstract September 2016

Intravitreal injection of rAAV2/2– ND4 (GS010): immune responses and ocular inflammation in non-human primates and patients with Leber Hereditary Optic Neuropathy (LHON)

Nitza Thomasson; Celine Bouquet; Anne Galy; Serge Fitoussi; Sandrine Meunier; Scott Uretsky; Catherine Vignal; Jose Sahel; Jean Philppe Combal

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1177. doi:

ARVO Annual Meeting Abstract June 2015

Relevance of NHP safety studies for ocular delivery of AAV-based gene therapy in humans: Example of GS010 (rAAV2/2- ND4 ) local tolerability, shedding and immunogenicity for the treatment of Leber Hereditary Optic Neuropathy (LHON), after intravitreal (IVT) injection in non-human primates (NHP) and in LHON patients.

Nitza Thomasson; Anne Galy; Serge Fitoussi; Sandrine Meunier; Scott Uretsky; Jean-Philippe Combal

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1087. doi:

ARVO Annual Meeting Abstract June 2015

Preliminary safety and tolerability results of intravitreal administration of GS010, a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing human wildtype mitochondrial NADH dehydrogenase 4 ( ND4 ) gene in patients with Leber Hereditary Optic Neuropathy (LHON) due to the G11778A ND4 mitochondrial DNA mutation

Jose Alain Sahel; Scott Uretsky; Jean Philppe Combal; Anne Galy; Nitza Thomasson; Serge Fitoussi; Marisol Corral-Debrinsky; Geraldine Honnet; Catherine Vignal

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1088. doi:

ARVO Annual Meeting Abstract April 2014

Safety, local tolerability and biodistribution of GS010 (AAV2/2-ND4), a gene therapy medicinal product in development for Leber Hereditary Optic Neuropathy (LHON)

Nitza Thomasson; Hélène Cwerman-Thibault; Sébastien Augustin; Manuel Simonuti; José-Alain Sahel; Didier Pruneau; Marie Montus; Anne Galy; Marisol Corral-Debrinski

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3340. doi:

Advertisement